"159"^^ . "2007-01-01+01:00"^^ . . "V\u00FDzk. z\u00E1m\u011Br nepochybn\u011B p\u0159isp\u011Bl k metodick\u00E9mu rozvoji v d\u016Fle\u017Eit\u00E9m oboru krevn\u00EDch malignit. V\u00FDzkumn\u00FD t\u00FDm, kter\u00FD byl de facto formov\u00E1n zcela nov\u011B, pro\u0161el v pr\u016Fb\u011Bhu \u0159e\u0161en\u00ED z\u00E1sadn\u00EDmi zm\u011Bnami. Tento fakt p\u0159inesl zm\u011Bny v harmonogramu \u0159e\u0161en\u00ED, ale z\u00E1v\u011Bre\u010Dn\u00E9 obdob\u00ED \u0159e\u0161en\u00ED v\u00FDzkumn\u00E9ho z\u00E1m\u011Bru p\u0159ineslo odpov\u00EDdaj\u00EDc\u00ED publika\u010Dn\u00ED uplatn\u011Bn\u00ED tohoto t\u00FDmu."@cs . . . . "0"^^ . "0"^^ . . "multiple myeloma; monoclonal gammapathies"@en . "159"^^ . "1"^^ . . . "From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies"@en . "2013-01-25+01:00"^^ . . . "Od klasick\u00FDch prognostick\u00FDch marker\u016F ke klinicky aplikovateln\u00FDm farmakogenomick\u00FDm a farmakoproteomick\u00FDm projekt\u016Fm u mnoho\u010Detn\u00E9ho myelomu a monoklon\u00E1ln\u00EDch gamapati\u00ED" . "Monoclonal gammapathies and multiple myeloma in particular are among the most common and debilitating malignancies in the elderly population. Treatment results have substantially improved and the probability of 10-year survival increased from 5% to 20% in the last decade. The treatment strategy today includes 3-5 regimens administered over a period of 10 years. There is increased tendency to apply treatment specifically tailored for a subgroup of patients with a well-defined risk and response rate. The aim of all these programs is to accelerate analysis of markers for prognosis. Older prognostic models are being modified and complemented by data from pharmacogenomic and, more recently, pharmacoproteomic studies. Newly, analysis, validation and evaluation of pharmacogenomic and pharmacoproteomic methods are activated for selection of optimal (high treatment response, low toxicity) and rational treatments for multiple myeloma. This is the main target of this Research Proposal."@en . "The Research plan added to the methodological development in the important area of blood malignances. The research team was established de novo and it was deeply reconstructed during experimental period. This fact brought changes in time sequence of the planned experiments, but in the final period of experimentation the publication output of this research project was substantially improved."@en . . . "Monoklon\u00E1ln\u00ED gamapatie, zvl\u00E1\u0161t\u011B pak mnoho\u010Detn\u00FD myelom pat\u0159\u00ED u star\u0161\u00ED populace mezi \u010Detn\u011Bj\u0161\u00ED, organizmus z\u00E1va\u017En\u011B po\u0161kozuj\u00EDc\u00ED n\u00E1dorov\u00E1 onemocn\u011Bn\u00ED. L\u00E9\u010Debn\u00E9 v\u00FDsledky se u t\u00E9to diagn\u00F3zy z\u00E1sadn\u011B b\u011Bhem deseti let zm\u011Bnily (5% versus 20% \u0161ance na desetilet\u00E9 p\u0159e\u017Eit\u00ED), t\u0159eba\u017Ee onemocn\u011Bn\u00ED je st\u00E1le nevyl\u00E9\u010Diteln\u00E9. L\u00E9\u010Debn\u00E1 strategie je dnes stanovov\u00E1na s v\u00FDhledem na 10 let. Projevuje se a uplat\u0148uje se snaha pou\u017E\u00EDt l\u00E9\u010Dbu \u0161itou na m\u00EDru skupin\u00E1m nemocn\u00FDch s definovan\u00FDm rizikem a definovanou \u0161anc\u00ED na \u00FAsp\u011Bch p\u0159i pou\u017Eit\u00ED ur\u010Dit\u00E9 l\u00E9\u010Dby. C\u00EDlem je doplnit prognostick\u00E9 modely o nejnov\u011Bj\u0161\u00ED postupy z oblasti farmakogenomiky \u010Di nejnov\u011Bji farmakoproteomiky a urychlit sb\u011Br a anal\u00FDzu dostupn\u00FDch prognostick\u00FDch parametr\u016F. Nov\u011B se uplatn\u00ED nalezen\u00ED farmakogenomick\u00FDch a farmakoproteomick\u00FDch metod, kter\u00E9 budou u\u017Eite\u010Dn\u00E9 pro racion\u00E1ln\u00ED v\u00FDb\u011Br l\u00E9\u010Debn\u00FDch postup\u016F u mnoho\u010Detn\u00E9ho myelomu. To je c\u00EDlem tohoto v\u00FDzkumn\u00E9ho z\u00E1m\u011Bru." . "2013-12-31+01:00"^^ . . "2014-06-30+02:00"^^ . . . . . . .